Read by QxMD icon Read

Acute myelogenous leukemia

Chunhao Niu, Xiaoying Sun, Weijing Zhang, Han Li, Liqun Xu, Jun Li, Benke Xu, Yanna Zhang
BACKGROUND: There is an abnormal expression of nuclear receptor subfamily 2 group F member 6 (NR2F6) in human cancers such as breast cancer, colon cancer, and acute myelogenous leukemia. However, its clinical significance in cervical cancer has not been established. We explored NR2F6 expression and its clinicopathological significance in early-stage cervical cancer. METHODS: NR2F6 expression in cervical cancer cell lines and cervical cancer tissues was determined by Western blotting, real-time PCR, and immunochemistry (IHC)...
October 20, 2016: International Journal of Molecular Sciences
R M Medrano-Juarez, D Sotello, M A Orellana-Barrios, L D'Cuhna, J D Payne, K Nugent
We present a case of acute hemolytic anemia, renal failure, and Clostridium perfringens bacteremia in a patient with acute myelogenous leukemia. The high fatality of C. perfringens bacteremia requires that clinicians recognize and rapidly treat patients at risk for this infection. Although other hemolytic processes are in the differential diagnosis of these events, the presence of high fever, chills, and rapidly positive blood cultures may help narrow the diagnosis. Most cases of C. perfringens bacteremia have a concomitant coinfection, which makes broad spectrum empiric therapy essential...
2016: Case Reports in Infectious Diseases
Kevin Shen, Stacy V Smith, Andrew G Lee
No abstract text is available yet for this article.
October 2016: Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie
G-Y Li, J-Z Liu, L Zhang, S-J Li, G-Z Liu, T-W Xiao, J-X Wang, L-X Wang, M Hou
Serine/threonine protein phosphatase 5 (PPP5C) participates in multiple signaling pathways including cell cycle control and cell growth. PPP5C is involved in the progression of human breast cancer and hepatocellular carcinoma. However, its function in acute myelogenous leukemia (AML) remains unknown. In this study, we constructed a lentivirus system to knock down the expression level of PPP5C in leukemic cell line U937. Cell proliferation and cell cycles were assessed by MTT assay and flow cytometry respectively...
September 30, 2016: Cellular and Molecular Biology
Tamara K Moyo, Michael R Savona
Myelodysplastic syndromes (MDS) comprise a heterogeneous group of clonal hematologic malignancies characterized by a hypercellular bone marrow and morphologic dysplasia in one or more lineage (i.e., myeloid, erythroid, or megakaryocytic), presenting clinically with leukopenia, anemia, and/or thrombocytopenia and with a propensity to transform to acute myelogenous leukemia. Newer technologies such as next-generation sequencing have allowed better understanding of the genetic landscape in MDS. Nearly 80 % of MDS patients have at least one mutation, and approximately 40 recurrent somatic mutations have been identified to occur in >1 % of cases...
October 12, 2016: Current Hematologic Malignancy Reports
Motoshi Ichikawa
Myelodysplastic syndromes (MDS) are characterized by clonal proliferation of hematopoietic stem/progenitor cells and their apoptosis, and show a propensity to progress to acute myelogenous leukemia (AML). Although MDS are recognized as neoplastic diseases caused by genomic aberrations of hematopoietic cells, the details of the genetic abnormalities underlying disease development have not as yet been fully elucidated due to difficulties in analyzing chromosomal abnormalities. Recent advances in comprehensive analyses of disease genomes including whole-genome sequencing technologies have revealed the genomic abnormalities in MDS...
2016: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
Thayalan Dineshkumar, Vemuri Suresh, Ramadas Ramya, Krishnan Rajkumar
Granulocytic sarcoma (GS) is an extremely rare condition involving infiltration of myeloblasts or immature myeloid cells in an extramedullary site. It is also known as chloroma, myeloid sarcoma or extramedullary myeloid tumor. It usually occurs concomitantly with acute myelogenous leukemia or with the onset of blastic phase of chronic myelogenous leukemia. On rare occasions, it evolves even before the onset of leukemias, and when it precedes leukemias without any overt signs, it is referred to as the primary type...
September 2016: Journal of Oral and Maxillofacial Pathology: JOMFP
Karen Y P S Avelino, Isaac A M Frias, Norma Lucena-Silva, Renan G Gomes, Celso P de Melo, Maria D L Oliveira, César A S Andrade
In the last ten years, conjugated polymers started to be used in the immobilization of nucleic acids via non-covalent interactions. In the present study, we describe the construction and use of an electrochemical DNA biosensor based on a nanostructured polyaniline-gold composite, specifically developed for the detection of the BCR/ABL chimeric oncogene. This chromosome translocation is used as a biomarker to confirm the clinical diagnosis of both chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL)...
September 22, 2016: Colloids and Surfaces. B, Biointerfaces
Dilini C Gunasekara, Mary M Zheng, Tara Mojtahed, James R Woods, Tamer E Fandy, Mark V Riofski, Carlotta A Glackin, Hazem E Hassan, Julia Kirshner, David A Colby
Recent studies suggest that leukemia stem cells (LSCs) play a critical role in the initiation, propagation, and relapse of leukemia. Herein we show that (-)-15-methylene-eburnamonine, a derivative of the alkaloid (-)-eburnamonine, is cytotoxic against acute and chronic lymphocytic leukemias (ALL and CLL) and acute myelogenous leukemia (AML). The agent also decreases primary LSC frequency in vitro. The cytotoxic effects appear to be mediated via the oxidative stress pathways. Furthermore, we show that the compound kills AML, ALL, and CLL stem cells...
September 28, 2016: ChemMedChem
Aurelia B Fu, Erica I Hodgman, Lorraine S Burkhalter, Rachel Renkes, Tamra Slone, Adam C Alder
BACKGROUND: Central venous access devices (CVADs) play an important role in the management of pediatric oncology patients; unfortunately, they are also associated with potentially serious complication rates. We hypothesized that, despite the significantly different disease courses typical of acute lymphoblastic leukemia and acute myelogenous leukemia, there would be identifiable risk factors for premature CVAD removal. METHODS: We retrospectively studied clinical characteristics and procedure records for all patients admitted with a leukemia diagnosis at our institution from May 2009 to July 2014...
October 2016: Journal of Surgical Research
Daniel Medina, Kevin David, Yong Lin, Dale Schaar, Vimal Patel, Mecide Gharibo, Rajat Bannerji, Kelly Walton, Joseph Aisner, Arnold B Rabson, Roger Strair
No abstract text is available yet for this article.
September 23, 2016: Leukemia & Lymphoma
Nirali N Shah, David M Loeb, Hahn Khuu, David Stroncek, Tolu Ariyo, Mark Raffeld, Cindy Delbrook, Crystal L Mackall, Alan S Wayne, Terry J Fry
Relapse of hematologic malignancies is the primary cause of treatment failure after allogeneic hematopoietic stem cell transplantation (HCT). Treatment for post-HCT relapse using donor lymphocyte infusion (DLI) has limited utility, particularly in the setting of acute leukemia, and can result in the development of graft-versus-host disease (GVHD). The Wilms' tumor 1 (WT1) gene product is a tumor-associated antigen that is expressed in acute leukemia and other hematologic malignancies, with limited expression in normal tissues...
September 12, 2016: Biology of Blood and Marrow Transplantation
Keisuke Kawamoto, Hiroaki Miyoshi, Noriaki Yoshida, Jun Takizawa, Hirohito Sone, Koichi Ohshima
Myeloid sarcoma (MS) is an extramedullary tumor of immature myeloid cells. We analyzed 131 patients with MS, including: (1) de novo MS; (2) MS with concomitant acute myeloid leukemia (AML); (3) MS following myelodysplastic syndrome, myeloproliferative neoplasm, or chronic myelogenous leukemia; and (4) MS as a recurrence of AML. The most common development site was the lymph node. Testicular lesions were statistically more frequent in MS as a recurrence of AML than in other types of MS (P=0.0183). MS tended to lack myeloid markers (myeloperoxidase was present in 63...
September 14, 2016: American Journal of Surgical Pathology
Samip Master, Reinhold Munker, Zhenzhen Shi, Glenn Mills, Runhua Shi
BACKGROUND: The treatment of acute myeloid leukemia (AML) has made significant progress in the last 30 years; however, numerous factors affect outcomes in patients with AML. Well-known risk factors are age, cytogenetics, and treatment intensity. The purpose of our study was to investigate the effects of insurance status on the outcome of AML; age, Carlson comorbidity index, distance travelled to the treatment center, and type of treatment center were adjusted by analyzing data from National Cancer Database (NCDB)...
September 2016: Anticancer Research
Takuya Iyoda, Yumi Nagamine, Yoshitomi Nakane, Yuya Tokita, Shougo Akari, Kazuki Otsuka, Motomichi Fujita, Keisuke Itagaki, You-Ichi Takizawa, Hiroaki Orita, Toshiyuki Owaki, Jyunichi Taira, Ryo Hayashi, Hiroaki Kodama, Fumio Fukai
The acquisition of drug resistance mediated by the interaction of tumor cells with the extracellular matrix (ECM), commonly referred to as cell adhesion-mediated drug resistance (CAM-DR), has been observed not only in hematopoietic tumor cells but also in solid tumor cells. We have previously demonstrated that a 22-mer peptide derived from fibronectin, FNIII14, can inhibit cell adhesion through the inactivation of β1 integrin; when coadministered with cytarabine, FNIII14 completely eradicates acute myelogenous leukemia by suppressing CAM-DR...
2016: PloS One
Shahram Teimourian, Ehsan Moghanloo
Abnormal cell differentiation, in particular suppression of terminal cell differentiation, exists in all tumors. Therapeutic interventions to restore terminal differentiation ("differentiation therapy") are a very attractive way to treat cancer, especially leukemia. A variety of chemicals stimulates differentiation of leukemic cells, such as dimethyl sulfoxide (DMSO) and all-trans retinoic acid (ATRA). Tumor suppressor genes have a vital role in the gateway to terminal cell differentiation. In this study, we inhibited PTEN tumor suppressor gene expression by siRNA to investigate the effect of potentiating cell survival and inhibiting apoptosis on HL-60 cell differentiation by DMSO and ATRA...
October 2016: DNA and Cell Biology
Ashley E J Rogers, Kristen M Eisenman, Susan A Dolan, Kristin M Belderson, Jocelyn R Zauche, Suhong Tong, Jane Gralla, Joanne M Hilden, Michael Wang, Kelly W Maloney, Samuel R Dominguez
BACKGROUND: Central line-associated blood stream infections (CLABSIs) are a source of high morbidity and mortality in children with acute myelogenous leukemia (AML). PROCEDURE: To understand the epidemiology and risk factors associated with the development of CLABSI in children with AML. METHODS: We retrospectively reviewed all patients with AML over a 5-year period between 2007 and 2011 at the Children's Hospital Colorado. Cases and controls were classified on the basis of the presence of a CLABSI as defined by the National Healthcare Safety Network...
September 12, 2016: Pediatric Blood & Cancer
Wen-Han Chang, Huey-Lan Huang, Wei-Pang Huang, Chien-Chih Chen, Yu-Jen Chen
Armillaridin (AM) is an aromatic ester compound isolated from Armillaria mellea. Treatment with AM markedly reduced the viability of human chronic myelogenous leukemia K562, chronic erythroleukemia HEL 92.1.7, and acute monoblastic leukemia U937 cells, but not normal human monocytes, in a dose- and time-dependent manner. Treatment of K562 cells with AM caused changes characteristic of autophagy. Only a small amount of AM-treated K562 cells exhibited apoptosis. By contrast, AM treatment resulted in extensive apoptotic features in U937 and HEL 92...
September 3, 2016: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
Shanshan Pei, Mohammad Minhajuddin, Angelo D'Alessandro, Travis Nemkov, Brett M Stevens, Biniam Adane, Nabilah Khan, Fred K Hagen, Vinod K Yadav, Subhajyoti De, John M Ashton, Kirk C Hansen, Jonathan A Gutman, Daniel A Pollyea, Peter A Crooks, Clayton Smith, Craig T Jordan
Although multidrug approaches to cancer therapy are common, few strategies are based on rigorous scientific principles. Rather, drug combinations are largely dictated by empirical or clinical parameters. In the present study we developed a strategy for rational design of a regimen that selectively targets human acute myelogenous leukemia (AML) stem cells. As a starting point, we used parthenolide, an agent shown to target critical mechanisms of redox balance in primary AML cells. Next, using proteomic, genomic, and metabolomic methods, we determined that treatment with parthenolide leads to induction of compensatory mechanisms that include up-regulated NADPH production via the pentose phosphate pathway as well as activation of the Nrf2-mediated oxidative stress response pathway...
October 14, 2016: Journal of Biological Chemistry
Jonathan Kenyon, Gabrielle Nickel-Meester, Yulan Qing, Gabriela Santos-Guasch, Ellen Drake, PingfuFu, Shuying Sun, Xiaodong Bai, David Wald, Eric Arts, Stanton L Gerson
Normal human hematopoietic stem and progenitor cells (HPC) lose expression of MLH1, an important mismatch repair (MMR) pathway gene, with age. Loss of MMR leads to replication dependent mutational events and microsatellite instability observed in secondary acute myelogenous leukemia and other hematologic malignancies. Epigenetic CpG methylation upstream of the MLH1 promoter is a contributing factor to acquired loss of MLH1 expression in tumors of the epithelia and proximal mucosa. Using single molecule high-throughput bisulfite sequencing we have characterized the CpG methylation landscape from -938 to -337 bp upstream of the MLH1 transcriptional start site (position +0), from 30 hematopoietic colony forming cell clones (CFC) either expressing or not expressing MLH1...
2016: International Journal of Stem Cell Research and Therapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"